Enjoy complimentary customisation on priority with our Enterprise License!
The bronchiectasis drugs market size is estimated to grow at a CAGR of 9.98% between 2022 and 2027. The market size is forecast to increase by USD 326.01 million. The growth of the market depends on several factors, including the increasing cases of associated risk factors, the availability of low-cost off-label generics, and the surge in the geriatric population.
This bronchiectasis drugs market report extensively covers market segmentation by product (antibiotics, expectorants, and others), distribution channel (offline and online), and geography (North America, Europe, Asia, and Rest of the World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, View Report Sample
The Increasing cases of associated risk factors are notable driving the market growth, although factors such as the growing awareness about bronchiectasis ?may impede?the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing cases of associated risks are the key factor driving the growth of the bronchiectasis drugs market. Bronchiectasis frequently happens due to health conditions such as humoral immunodeficiency, inflammatory bowel disease (Crohn's disease and ulcerative colitis), rheumatologic diseases (rheumatoid arthritis and Sjogren's disease), chronic obstructive pulmonary disease (COPD), cystic fibrosis. Across the globe, these diseases are of great concern. The increased prevalence of bronchiectasis globally is also a result of various external factors, including an increase in the number of patients with related diseases.
The external factors include exposure to poisonous gases owing to various occupations such as mining, working in chemical laboratories and manufacturing plants, increasing air pollution, and growing smoking habits. Therefore growing cases of risk factors and increased exposure to different forms of poisonous gases are increasing the probability of bronchiectasis infection. The need for treatment options is increasing as a result of the multitudinous etiology of bronchiectasis, it is expected to have a positive impact on the global bronchiectasis drugs market over the forecast period.
The growing awareness about bronchiectasis is the primary trend in the bronchiectasis drug market. Bronchiectasis is often misunderstood as a common cough and cold, as the symptoms of most respiratory tract infections are overlapped. This results in underdiagnosing the infection, which reduces the use of treatment options and thus affects the growth of the market. In order to increase the prevalence of this disease, primary and secondary healthcare centers need to be better informed about it.
Many awareness programs have been put in place by a number of public and private organizations across the world to inform people about this. In addition, some companies are regularly organizing educational programs to inform healthcare professionals and patients of available therapeutic options for the treatment of bronchiectasis. Such awareness programs about the medications available for the treatment of bronchiectasis are expected to positively impact the market during the forecast period.
The lack of approved drugs for bronchiectasis is the major challenge to the growth of the global bronchiectasis drug market. The treatment options for bronchiectasis consist of medications, CPT, the use of lung airway devices, oxygen therapy, and surgery. The reason for the infection in bronchiectasis can be different, but a wide range of treatments is required in some cases. There are no authorized products in the global bronchiectasis drug market at present. However, drugs are used as OTC and off-label drug therapies largely to relieve the symptoms of other conditions, thus increasing the risk of bronchiectasis. However, human use of antibiotics leads to a process of drug resistance.
Moreover, patient adherence to treatment continues to decline as a result of resistance to antibiotics. The growth of the market is projected to be limited due to the lack of availability of approved medicinal products, along with a weak therapeutic effect of Symptomative Medicines. In addition, there are only a few drugs available for the treatment of bronchiectasis. Also, R & D is focused more on the development of substitute therapies. Thus, the lack of approved drug therapies is expected to hinder the growth of the market in focus during the forecast period
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Bronchiectasis Drugs Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product launches, to enhance their presence in the market.
AbbVie Inc.: The company offers breast cancer therapeutics such as Veliparib, a PARP inhibitor.
The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market vendors, including
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the antibiotics segment will be significant during the forecast period. This segment consists of a wide range of off-label drugs, such as azithromycin, erythromycin, doxycycline, amoxicillin, ciprofloxacin, and macrolides, which are used for the treatment of bronchiectasis. Due to the absence of approved drug therapy for bronchiectasis, these antibiotics are very common in use.
Get a glance at the market contribution of various segments View the PDF Sample
The antibiotics segment ?was valued at?USD 225.46 million?in 2017 and continue to grow by 2021. The treatment of bronchiectasis with antibiotics is broadly classified as exacerbation treatment, chronic suppressive treatment, and eradication treatment. Antibiotic resistance in patients poses a challenge to the growth of the segment. A single antibiotic may not be able to inhibit all pathogens present and near the respiratory tract, even if every pathogen associated with the respiratory system is resistant to various antibiotics. Therefore, in order to attain the aim of a clinically meaningful result, different antibiotics must be used with each other.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. In this region, the increasing sales of various off-label drug therapies approved for other chronic respiratory conditions and the increasing prevalence of chronic respiratory diseases have fueled the growth of the bronchiectasis drug market.
The COVID-19 pandemic had a negative impact on the growth of the regional bronchiectasis drugs market in 2020. However, in December 2020, the initiation of COVID-19 vaccination drives and the subsequent lifting of lockdown restrictions led to the gradual resumption of operations in pharmaceutical manufacturing and logistics units, which helped in easing R&D-related constraints. The regional bronchiectasis drugs market is expected to witness growth during the forecast period.
The bronchiectasis drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Technavio categorizes the as a part of the global bronchiectasis drugs market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent, the global pharmaceuticals, market covers products and companies engaged in research and development (R&D) or production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.
Bronchiectasis Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
168 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9.98% |
Market growth 2023-2027 |
USD 326.01 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
9.09 |
Regional analysis |
North America, Europe, Asia, and Rest of the World (ROW) |
Performing market contribution |
North America at 44% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Akorn Operating Co LLC, Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Dr Reddys Laboratories Ltd., Endo International Plc, GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd., Neopharma Corp., Pfizer Inc., Reckitt Benckiser Group Plc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Virtus Pharmaceuticals LLC, Wockhardt Ltd., and Zydus Lifesciences Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.